The DAT is performed to determine if red cells have been sensitized in vivo by antibodies and/or complement factor (C3d). This test is especially used :
- if an autoimmune hemolytic anemia is suspected,
- to help diagnose hemolytic disease of the newborn (HDN) due to an incompatibility between the blood types of a mother and baby
- to investigate a suspected transfusion reaction.
Thus the patient's red cells are directly tested with human antiglobulin anti-IgG or anti-C3d. Through its new test featuring EM Technology, DIAGAST provides greater benefits for customers:
Feel free to contact our Product manager Fanny DENIS for further information on this new test.